IDYA
Price
$24.27
Change
-$0.08 (-0.33%)
Updated
Aug 1 closing price
Capitalization
2.12B
10 days until earnings call
IOVA
Price
$2.68
Change
+$0.11 (+4.28%)
Updated
Aug 1 closing price
Capitalization
894.94M
5 days until earnings call
Interact to see
Advertisement

IDYA vs IOVA

Header iconIDYA vs IOVA Comparison
Open Charts IDYA vs IOVABanner chart's image
IDEAYA Biosciences
Price$24.27
Change-$0.08 (-0.33%)
Volume$860.81K
Capitalization2.12B
Iovance Biotherapeutics
Price$2.68
Change+$0.11 (+4.28%)
Volume$16.67M
Capitalization894.94M
IDYA vs IOVA Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. IOVA commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and IOVA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (IDYA: $24.27 vs. IOVA: $2.68)
Brand notoriety: IDYA and IOVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 77% vs. IOVA: 113%
Market capitalization -- IDYA: $2.12B vs. IOVA: $894.94M
IDYA [@Biotechnology] is valued at $2.12B. IOVA’s [@Biotechnology] market capitalization is $894.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileIOVA’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • IOVA’s FA Score: 1 green, 4 red.
According to our system of comparison, both IDYA and IOVA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while IOVA’s TA Score has 7 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • IOVA’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, IOVA is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -0.94% price change this week, while IOVA (@Biotechnology) price change was -14.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

IOVA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.12B) has a higher market cap than IOVA($895M). IDYA YTD gains are higher at: -5.564 vs. IOVA (-63.784). IOVA (-354.01M) and IDYA (-356.46M) have comparable annual earnings (EBITDA) . IDYA has more cash in the bank: 693M vs. IOVA (360M). IDYA has less debt than IOVA: IDYA (26M) vs IOVA (53.7M). IOVA has higher revenues than IDYA: IOVA (213M) vs IDYA (7M).
IDYAIOVAIDYA / IOVA
Capitalization2.12B895M237%
EBITDA-356.46M-354.01M101%
Gain YTD-5.564-63.7849%
P/E RatioN/AN/A-
Revenue7M213M3%
Total Cash693M360M193%
Total Debt26M53.7M48%
FUNDAMENTALS RATINGS
IDYA vs IOVA: Fundamental Ratings
IDYA
IOVA
OUTLOOK RATING
1..100
1575
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
72100
SMR RATING
1..100
9396
PRICE GROWTH RATING
1..100
5061
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IOVA's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for IDYA (63) in the null industry. This means that IOVA’s stock grew somewhat faster than IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (72) in the null industry is in the same range as IOVA (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to IOVA’s over the last 12 months.

IDYA's SMR Rating (93) in the null industry is in the same range as IOVA (96) in the Biotechnology industry. This means that IDYA’s stock grew similarly to IOVA’s over the last 12 months.

IDYA's Price Growth Rating (50) in the null industry is in the same range as IOVA (61) in the Biotechnology industry. This means that IDYA’s stock grew similarly to IOVA’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as IOVA (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to IOVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAIOVA
RSI
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 11 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IRFAX8.90N/A
N/A
Cohen & Steers International Realty A
FAEGX20.61N/A
N/A
Fidelity Advisor Equity Growth M
PABYX16.75N/A
N/A
Putnam Dynamic Asset Allocation Bal Y
DGLAX20.78N/A
N/A
BNY Mellon Global Stock - A
PGJCX17.52N/A
N/A
PGIM Jennison Global Infrastructure C